08:24 AM EST, 01/13/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) has agreed to acquire Intra-Cellular Therapies ( ITCI ) for about $14.6 billion in cash, the companies said Monday.

The $132-per-share deal includes Caplyta, a once-daily oral therapy approved by the Food and Drug Administration for schizophrenia and bipolar depression, along with a clinical-stage pipeline, the companies said.

The deal will likely close later in 2025, subject to regulatory and shareholder approvals, the companies added.

Shares of Intra-Cellular Therapies ( ITCI ) were up 35% in premarket trading, while Johnson & Johnson ( JNJ ) was little changed.